Insider · CIK 0001194459
William F Doyle
Files at NVCR (NovoCure Ltd), ELAN (Elanco Animal Health Inc), PROK (PROKIDNEY CORP.). First filing Mar 5, 2026, latest Mar 5, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NVCR: NovoCure Ltd
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 64Notable | NovoCure Ltd | $933k 71,887 shares | -18% | +33% from low-38% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | NVCR NovoCure Ltd | AGrant or award Ordinary Shares | +200,000 | $0.00 | $0 | 200,000 | Mar 5, 2026 |
| Mar 3, 2026 | NVCR NovoCure Ltd | AGrant or award Ordinary Shares | +200,284 | $0.00 | $0 | 400,284 | Mar 5, 2026 |
| Mar 3, 2026 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -50,557 | $12.79 | $646k | 349,727 | Mar 5, 2026 |
| Mar 3, 2026 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -21,330 | $13.43 | $286k | 328,397 | Mar 5, 2026 |
| Mar 3, 2026 | NVCR NovoCure Ltd | AGrant or award Stock Option (Right to Buy)derivative | +258,445 | $0.00 | $0 | 258,445 | Mar 5, 2026 |
| Mar 3, 2026 | NVCR NovoCure Ltd | AGrant or award Stock Option (Right to Buy)derivative | +30,072 | $0.00 | $0 | 288,517 | Mar 5, 2026 |
| May 29, 2025 | PROK PROKIDNEY CORP. | AGrant or award Director stock option (right to buy)derivative | +125,862 | $0.00 | $0 | 125,862 | Jun 2, 2025 |
| Nov 29, 2024 | ELAN Elanco Animal Health Inc | AGrant or award Common Stock | +18,169 | $0.00 | $0 | 94,499 | Dec 3, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.